MetaLight Inc. has convened its 2026 annual general meeting (AGM) for 11:00 a.m. on Monday, 22 June 2026, at 1/F, Liangdian Creative Park, No. 94 Dongsishitiao Street, Dongcheng District, Beijing, PRC.
Key items on the agenda include:
1. Financial reporting • Shareholders will review and adopt the audited consolidated financial statements for the year ended 31 December 2025, together with reports from the directors and independent auditor.
2. Board composition • Re-election of four executive directors—Dr. Sun Xi, Ms. Qian Jinlei, Mr. Xu Cheng and Mr. Xiao Pingyuan—and two independent non-executive directors, Dr. Xiong Yingfei and Mr. Huang Xiaoling.
3. Remuneration matters • Authorisation for the board to determine directors’ remuneration. • Re-appointment of Ernst & Young as external auditor, with the board authorised to set audit fees.
4. Capital mandates • Share repurchase mandate: authority to buy back up to 10% of the company’s issued shares (excluding treasury shares and pending cancellations) during the mandate period. • Issuance mandate: authority to allot and issue new shares or convertible securities up to 20% of issued share capital, subject to Listing Rules exemptions for rights issues, share option exercises, scrip dividends and specific shareholder approvals. • Extension mandate: potential expansion of the issuance limit by adding the number of shares repurchased under the buy-back mandate, capped at an additional 10% of issued shares.
Procedural details
• All resolutions will be decided by poll, with results published on the Hong Kong Exchanges and Clearing Limited website and the company’s site. • Proxy forms must be lodged with Computershare Hong Kong Investor Services Limited by 11:00 a.m., Saturday, 20 June 2026. • The share register will be closed from Tuesday, 16 June 2026 to Monday, 22 June 2026 (both days inclusive); only shareholders on record as of 22 June 2026 may vote.
As of the notice date (29 May 2026), MetaLight’s board comprises four executive directors—Dr. Sun Xi (Chairman & CEO), Ms. Qian Jinlei, Mr. Xu Cheng and Mr. Xiao Pingyuan—and three independent non-executive directors—Dr. Xiong Yingfei, Ms. Su Yu and Mr. Huang Xiaoling.
Comments